A Phase I, Three-part Study to Determine the Maximum Tolerated Dose/Recommended Dose (Part 1), Compare Bioavailability in the Fed and Fasted States (Part 2), and Evaluate Safety and Tolerability (Part 3) of a Novel Oral Arsenic Trioxide Formulation (ORH-2014), in Subjects With Advanced Hematological Disorders

Trial Profile

A Phase I, Three-part Study to Determine the Maximum Tolerated Dose/Recommended Dose (Part 1), Compare Bioavailability in the Fed and Fasted States (Part 2), and Evaluate Safety and Tolerability (Part 3) of a Novel Oral Arsenic Trioxide Formulation (ORH-2014), in Subjects With Advanced Hematological Disorders

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Arsenic trioxide (Primary)
  • Indications Haematological disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Orsenix
  • Most Recent Events

    • 15 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top